Trial · NCT07061847
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847, Phase 2, Recruiting, Northwell Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines. Trials, record NCT07061847. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07061847
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
- NCT number
- NCT07061847
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Northwell Health
- Conditions
- Migraine
- Interventions
- Lidocaine (drug), Lidocaine Procedure
- First posted
- 2025-07-11
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction in Monthly Migraine Headache Days | From enrollment to post-treatment at 3 months | To observe a ≥50% reduction in monthly migraine headache days in one month post intra-arterial lidocaine infusion into the bilateral middle meningeal artery. |
| Secondary | ≥50% reduction in migraine headache intensity at 15 minutes, 2 hours, and 24 hours post procedure. | 15 minutes, 2 hours, and 24 hours post-procedure. | |
| Secondary | Sustained freedom from headache pain >48hrs. | >48hrs post treatment | |
| Secondary | Percentage of patients achieving ≥75% and 100% reduction in monthly headache days at 1 month and 3 months | At 1 month and 3 month post procedure | |
| Secondary | Mean number of monthly migraine headaches days at 1 month and 3 months. | From enrollment to 1 month and 3 months post procedure | |
| Secondary | Mean change from baseline in the Global Assessment of Migraine Severity (GAMS) at 3 months | From enrollment to 3 months post procedure | |
| Secondary | Percent with improvement in Migraine Disability Assessment (MIDAS) at 3 months from severe disability (Grade IV, score ≥21) to no moderate disability (Grade I to III, score 0-21) | From enrollment to 3 month post procedure | |
| Secondary | Percent Headache Impact Test (HIT)-6 score <50 at 3 months. | From enrollment to 3 months post procedure | |
| Secondary | Percent with reduction in need for analgesic use by ≥50% at 3 months. | From enrollment to 3 months post procedure | |
| Secondary | Adverse events at 24 hours and 3 months post-procedure. | From enrolllment to 3 months post procedure |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07061847
GET https://conductscience.org/api/trials/v1/NCT07061847/registered